Funding intended to fuel continued innovation of RapidAI’s advanced clinical decision and workflow support technology; further establish a leadership position in clinical AI solutions
RapidAI, a global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, announced $75 million in Series C funding led by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on the enterprise software, data and technology markets. The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals.
Latest Fintech Interview: Global Fintech Interview with Ralph Dangelmaier, CEO & Board Member at BlueSnap
“RapidAI is playing an outsized role in advancing patient care for life-threatening diseases with innovative clinical AI solutions. We look forward to our partnership and helping the company realize its next phase of growth.”
“Hospitals are increasingly looking for RapidAI solutions to solve their critical needs, including helping care teams work more efficiently and support clinical decision making for better patient outcomes,” said Karim Karti, CEO of RapidAI. “RapidAI’s advanced clinical decision support (CDS) software goes beyond simple triage and notification to provide specific, relevant and contextual data with tremendous accuracy to satisfy these demands. Vista Credit Partners’ support and access to their expertise will advance our vision, technological innovation and go-to-market efforts as we further establish our leadership position in clinical AI solutions for life-threatening diseases.”
Read More About Fintech Interview: Global Fintech Interview with Marc Kuzak, Vice President of Legal at Yapily
RapidAI’s pioneering AI and workflow technology sets the standard for stroke care – the second leading cause of death globally. The company has built a comprehensive portfolio of stroke solutions, including Rapid NCCT Stroke – the first and only FDA-cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from non-contrast CT imaging. Rapid NCCT Stroke provides hospitals of all sizes and imaging capabilities greater access to imaging and decision support to address a wider population of patients. RapidAI has expanded into new disease states with FDA-cleared modules for cerebral aneurysm management and the identification and notification of suspected central pulmonary embolism. The company is also developing additional modules for other disease states.
Recent milestones demonstrating RapidAI’s platform innovation and market traction include:
- Surpassed 10 million scans analyzed on the platform;
- Published in over 300 peer reviewed publications;
- Deployed in over 2,200 hospitals in 100+ countries; and
- Leveraged in over 25 clinical trials.
“Vista Credit Partners provides mission-critical enterprise software businesses with flexible capital solutions and operational support to accelerate growth and category leadership,” said David Flannery, President of Vista Credit Partners. “RapidAI is playing an outsized role in advancing patient care for life-threatening diseases with innovative clinical AI solutions. We look forward to our partnership and helping the company realize its next phase of growth.”
Browse The Complete Interview About Fintech: Global Fintech Interview with Poorvi Sachar, Head of Operations at Tezos India
[To share your insights with us, please write to sghosh@martechseries.com]
